The use of oral anticoagulants in the management of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is the object of an article published in “Blood Reviews” on 4 September 2024 which examines the current evidence on oral anticoagulant use in PAH and CTEPH and discusses the implications of drug-drug interactions within the current context of multi-drug treatments, including targeted drugs in PAH.
Read the full article at this link
Citation
Escal J, Poenou G, Delavenne X, Bezzeghoud S, Mismetti V, Humbert M, Montani D, Bertoletti L. Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH. Blood Rev. 2024 Sep 4:101240. doi: 10.1016/j.blre.2024.101240. Epub ahead of print. PMID: 39245607.